Skip to main content
HYPD
NASDAQ Life Sciences

Hyperion DeFi Q2 10-Q: Record $31M Net Income, Material Weakness Remediated, HYPE Price Drop Hits Treasury

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$2.83
Mkt Cap
$40.774M
52W Low
$2.34
52W High
$15
52W Position info
21% above low
Off High info
81% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

HYPD sits 21% above its 52-week low of $2.34 on light trading volume (0.3× avg).

Summary

Hyperion DeFi reported record Q2 net income of $31.0 million, remediated a material weakness in internal controls, and disclosed new HAUS agreements, but subsequent HYPE price decline reduced treasury value by $10.9 million.


Key Events · Earnings and Guidance · HYPD

  • Record Q2 Net Income

    Net income of $30.95 million for Q2 2026, driven by $34.8 million in realized and unrealized gains on HYPE digital assets, compared to a net loss of $8.69 million in Q2 2025.

  • Material Weakness Remediated

    Management concluded that the previously disclosed material weakness in internal control over financial reporting related to digital asset pricing validation has been remediated as of June 30, 2026.

  • HYPE Price Decline Post-Quarter

    HYPE price fell from $65.00 on June 30, 2026 to $55.40 on August 10, 2026, resulting in an approximate $10.9 million fair value decline on the company's 1.1 million HYPE tokens.

  • New HAUS Agreements

    Entered HAUS agreements with Skew (July 15, 2026) and Bursa (August 10, 2026), each supplying 500,000 HYPE tokens to support custom markets, with the company earning trading fees plus 100% of staking rewards.


Analysis · HYPD · Life Sciences

Hyperion DeFi's Q2 10-Q confirms record net income of $31.0 million, driven by $34.8 million in realized and unrealized gains on HYPE digital assets. The company also disclosed remediation of a previously identified material weakness in internal controls over digital asset pricing, a positive governance development. However, subsequent events reveal a $10.9 million fair value decline in HYPE holdings as the token price fell from $65.00 to $55.40 by August 10, 2026, underscoring the extreme volatility of the company's treasury strategy. New HAUS agreements with Skew and Bursa, each supplying 500,000 HYPE tokens, expand revenue-generating partnerships but also increase exposure to HYPE price fluctuations.

At the time of this filing, HYPD was trading at $2.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.8M. The 52-week trading range was $2.34 to $15.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HYPD - Latest Insights

HYPD
Aug 12, 2026, 5:19 PM EDT
Source: The Block
Importance Score:
7
HYPD
Aug 12, 2026, 4:15 PM EDT
Source: Reuters
Importance Score:
8
HYPD
Aug 12, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
HYPD
Jul 15, 2026, 3:00 PM EDT
Source: Reuters
Importance Score:
7
HYPD
Jul 08, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
8